The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma

In the ASTRUM-007 randomized double-blind phase III study, Song et al.(1) showed that the combination of PD-1 inhibitors with first-line fluoropyrimidine and platinum-based chemotherapy improves outcomes in PD-L1-overexpressing esophageal squamous cell carcinomas.

Detalles Bibliográficos
Autores principales: van Laarhoven, Hanneke W.M., Derks, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140387/
https://www.ncbi.nlm.nih.gov/pubmed/37075702
http://dx.doi.org/10.1016/j.xcrm.2023.100990
Descripción
Sumario:In the ASTRUM-007 randomized double-blind phase III study, Song et al.(1) showed that the combination of PD-1 inhibitors with first-line fluoropyrimidine and platinum-based chemotherapy improves outcomes in PD-L1-overexpressing esophageal squamous cell carcinomas.

Ejemplares similares